ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
XTL Biopharmaceuticals Ltd

XTL Biopharmaceuticals Ltd (XTLB)

1.9399
-0.0301
(-1.53%)
Closed December 07 4:00PM
1.9399
0.00
(0.00%)
After Hours: 6:10PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
1.9399
Bid
1.80
Ask
2.33
Volume
16,772
1.7816 Day's Range 1.96
0.00 52 Week Range 0.00
Market Cap
Previous Close
1.97
Open
1.96
Last Trade
192
@
1.9399
Last Trade Time
Financial Volume
$ 32,611
VWAP
1.9444
Average Volume (3m)
-
Shares Outstanding
5,449,061
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-1.78M

About XTL Biopharmaceuticals Ltd

XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic ... XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Ramat Gan, Center, Isr
Founded
-
XTL Biopharmaceuticals Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker XTLB. The last closing price for XTL Biopharmaceuticals was $1.97. Over the last year, XTL Biopharmaceuticals shares have traded in a share price range of $ 0.00 to $ 0.00.

XTL Biopharmaceuticals currently has 5,449,061 shares outstanding. The market capitalization of XTL Biopharmaceuticals is $10.73 million.

XTLB Latest News

XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million

expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Completed a Private Placement...

XTL Entered Definitive Agreement to Acquire The Social Proxy

expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
UPCUniverse Pharmaceuticals Inc
$ 3.38
(221.90%)
93.72M
LIFWMSP Recovery Inc
$ 3.2461
(104.16%)
29.08M
GXAIGaxos ai Inc
$ 2.5801
(81.70%)
146.21M
SBETSharpLink Gaming Inc
$ 0.9116
(73.97%)
27.09M
HCTIHealthcare Triangle Inc
$ 1.165
(68.38%)
4.34M
ORISOriental Rise Holdings Ltd
$ 3.6833
(-93.42%)
27.58M
LICNLichen China Limited
$ 0.4895
(-76.91%)
186.02M
MYNAMynaric AG
$ 0.499246
(-64.59%)
3.62M
CEROCERo Therapeutics Holdings Inc
$ 0.1146
(-40.16%)
38.21M
BTCTBTC Digital Ltd
$ 10.50
(-32.95%)
3.31M
SMXSMX Security Matters Public Company
$ 0.4879
(64.06%)
448.58M
SOUNSoundHound AI Inc
$ 15.01
(12.60%)
218.94M
NVDANVIDIA Corporation
$ 142.44
(-1.81%)
187.57M
LICNLichen China Limited
$ 0.4895
(-76.91%)
186.02M
SVMHSRIVARU Holding Ltd
$ 0.0293
(-16.29%)
162.46M

XTLB Discussion

View Posts
glenn1919 glenn1919 1 month ago
XTLB.....................https://stockcharts.com/h-sc/ui?s=XTLB&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 8 months ago
XTLB under $3
👍️0
glenn1919 glenn1919 8 months ago
XTLB......................................https://stockcharts.com/h-sc/ui?s=XTLB&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 8 months ago
XTLB under $3
👍️0
Monksdream Monksdream 8 months ago
XTLB new 52 hi
👍️0
Pedro2004 Pedro2004 8 months ago
Schwabb won't let me short companies likes this.
👍️0
Pedro2004 Pedro2004 8 months ago
Nice little pump and dump today.
👍️0
Pedro2004 Pedro2004 8 months ago
Another scam Israeli company.
👍️0
Monksdream Monksdream 9 months ago
XTLB new 52 hi
👍️0
Zardiw Zardiw 9 months ago
$XTLB Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:



Z
👍️0
Monksdream Monksdream 9 months ago
XTLB new 52 week hi
👍️0
Awl416 Awl416 9 months ago
XTL To Aquire The Social Proxy
👍️0
stock1ace1 stock1ace1 9 months ago
27k vol unusual vol 2 days before run looks like some insiders knew the news was coming …
👍️0
stock1ace1 stock1ace1 3 years ago
running !
👍️0
trendzone trendzone 3 years ago
Halted shorts about to get ripped apart
👍️0
stock1ace1 stock1ace1 3 years ago
News Watch Latest Pr Co Seeking Partnership/Merger

The Company is expanding its IP portfolio surrounding hCDR1 and has decided, at this time, to explore cooperation with a strategic partner in order to execute its clinical trials. In parallel, the Company will look to expand and identify additional assets to add to XTL’s portfolio.
👍️0
alchemytrader alchemytrader 3 years ago
volume
👍️0
stock1ace1 stock1ace1 3 years ago
$3.62 Macd crossover #bullish -> https://stockcharts.com/h-sc/ui?s=Xtlb
👍️0
stock1ace1 stock1ace1 3 years ago
XTLb is continually looking for late stage products to in-license or acquire. In addition, we are pursuing partnerships for the development and marketing of our products internationally. If your company has interest in discussing a potential business collaboration with XTL, please contact our business development department at: bd@xtlbio.com or call us at +972 9 955 7080.
👍️0
stock1ace1 stock1ace1 3 years ago
Company is seeking merger / partnership The Company is expanding its IP portfolio surrounding hCDR1 and has decided, at this time, to explore cooperation with a strategic partner in order to execute its clinical trials. In parallel, the Company will look to expand and identify additional assets to add to XTL’s portfolio.
👍️0
ClayTrader ClayTrader 4 years ago
* * $XTLB Video Chart 03-05-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
odds_are odds_are 4 years ago
Thanks for the link. Other boards seem to be clueless as to why the sharp increase in price.$XTLB
👍️0
AlphaStockNews AlphaStockNews 4 years ago
$XTLB is screaming for the top after a recent report shows massive growth in the company's target market. This is a clear acquisition target! https://cnafinance.com/xtlb-stock-xtl-biopharmaceuticals-is-rocketing/
👍️0
Awl416 Awl416 4 years ago
Good lord
👍️0
wesley_ wesley_ 4 years ago
$1.70 nice
👍️0
PennyStock Alert PennyStock Alert 5 years ago
http://barchart.com/quotes/stocks/XTLBY
👍️0
ClayTrader ClayTrader 7 years ago
* * $XTLB Video Chart 05-07-18 * *

Link to Video - click here to watch the technical chart video

👍️0
Joecanada13 Joecanada13 7 years ago
Boom!!!
👍️0
Tdash Tdash 7 years ago
hmmm
👍️0
Awl416 Awl416 8 years ago
55k
👍️0
PAC PAC 8 years ago
What was the volume AH yesterday?
👍️0
europtiger europtiger 8 years ago
There is some 3,50 Gifts
👍️0
europtiger europtiger 8 years ago
Woow afterhour
👍️0
stocktrademan stocktrademan 8 years ago
XTLB bullish 1.22




👍️0
Yo-Yo Yo-Yo 8 years ago
Whose driving this bus today, any catalyst here? GLTA!!!
👍️0
fortunebuilder1959 fortunebuilder1959 10 years ago
Will def have this on my radar; ready to jump in with any momentum....
👍️0
Arizzle Arizzle 10 years ago
I must have missed the pump too
👍️0
marcusjtrader marcusjtrader 10 years ago
XTLB is a clear pump and dump based on charting. The company hasn't had any news in over a month. Claim your shares to short now.
👍️0
Arizzle Arizzle 10 years ago
Multi-day run?
👍️0
jcseattle jcseattle 10 years ago
http://finance.yahoo.com/news/xtl-biopharmaceuticals-further-strengthens-team-120000879.html
👍️0
jcseattle jcseattle 10 years ago
(XTLB) Very good time to short it.
👍️0
AntiOne AntiOne 10 years ago
Boom...another pick skyrocket from BackPackOfStock
👍️0
Tradescott818 Tradescott818 10 years ago
No idea
👍️0
javier1973 javier1973 10 years ago
What happen?.
👍️0
Tradescott818 Tradescott818 10 years ago
Wowwowowowowowowoowow
👍️0
AntiOne AntiOne 10 years ago
Just picked a few shares....heard rumblings
👍️0
surf1944 surf1944 11 years ago
8:02AM XTL Biopharma announced it has signed a licensing agreement with Yeda Research and Development Company to develop hCDR1, (XTLB) 2.73 : Co announced it has signed a licensing agreement with Yeda Research and Development Company to develop hCDR1, a Phase II-ready asset for the treatment of Systemic Lupus Erythematosus.

Two placebo controlled Phase I trials and a placebo controlled Phase II trial were conducted by Teva Pharmaceutical (TEVA) which had previously in-licensed hCDR1 from Yeda. The Phase I and Phase II studies consisted of over 400 patients, demonstrating that hCDR1 is well tolerated by patients and has a favorable safety profile. The PRELUDE trial did not achieve its primary efficacy endpoint based on the SLEDAI scale, resulting in Teva returning the asset to Yeda. However, the PRELUDE trial showed encouraging results in its secondary clinical endpoint, the BILAG index, and, in fact, the 0.5 mg weekly dose showed a substantial effect. Multiple post-hoc analyses also showed impressive results for this dose using the BILAG index. Such dose will be the focus of the clinical development plan moving forward.

The FDA has since directed that the primary endpoint in future trials for Lupus therapies, including those for hCDR1, should be based on either the BILAG index or the SLE Responder Index. Given the FDA's recommendation and the positive findings from the PRELUDE trial, XTL intends to initiate a new Phase II clinical trial, which will include the 0.5 mg (and a 0.25 mg) weekly dose of hCDR1.

👍️0
Renee Renee 11 years ago
XTLBY changed to XTLB and uplisted to the Nasdaq NCM:

http://www.otcbb.com/asp/dailylist_detail.asp?d=07/12/2013&mkt_ctg=NON-OTCBB
👍️0
Renee Renee 12 years ago
XTLBY: 1-10 R/S concurrent with a ratio change. The ADR Ratio will change from [ one(1) ADS: two (2) Ordinary Share] to a new ratio of [ one (1) ADS: twenty (20) Ordinary Share]. Holders of XTL BioPharmaceuticals will be required on a mandatory basis to surrender their Old ADSs to BNY Mellon in exchange for the New ADSs. ONly whole DRs will be distributed.

http://www.otcbb.com/asp/dailylist_detail.asp?d=10/03/2012&mkt_ctg=NON-OTCBB
👍️0
Eugene_2009 Eugene_2009 12 years ago
Hello,
Is there more information over XTLBY?
👍️0

Your Recent History

Delayed Upgrade Clock